Premium
P3‐086: What is the cause of cognitive decline in MCI individuals who do not have amyloid?
Author(s) -
Chertkow Howard,
Nikelski James,
Vaitekunas Susan,
Bergman Howard,
Whitehead Victor,
Solomon Shelley
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.1305
Subject(s) - pittsburgh compound b , dementia , cognitive decline , medicine , cognitive impairment , depression (economics) , psychology , neuropsychology , montreal cognitive assessment , cognition , psychiatry , disease , economics , macroeconomics
compared for baseline demographics, disease severity and outcome. Results: Subjects with HA or amyloid burden were more likely to progress clinically (Table 1). Nearly 1/3 of subjects were discordant (Table 2). Eighteen subjects (18%) with HAwere amyloid negative. They were more likely to be male and older, less likely to be ApoE4 carriers, less likely to progress to dementia and had less of an increase in CDR-SOB score. Forty-three subjects (34%) who were amyloid positive did not have HA. They were slightly older but did not differ in gender or ApoE4 carrier status. They were less likely to progress to dementia and had less of an increase in DCDR-SOB score. Conclusions: Both amyloid burden and HA predicted greater risk for progression to dementia over 36 months. Requiring positive concordance of both biomarkers would have excluded half of subjects (82/164) but would have resulted inmaximal enrichment (72% progressing to dementia). Discordant subjects differed in demographics and outcome, and may constitute subgroups with either milder disease (amyloid positive but lacking HA) or non-Alzheimer’s pathology (HA but amyloid negative).